You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

MESALAMINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Mesalamine patents expire, and when can generic versions of Mesalamine launch?

Mesalamine is a drug marketed by Teva Pharms Usa, Alembic, Alkem Labs Ltd, Amta, Aurobindo Pharma Ltd, Mylan, Novast Labs, Sun Pharm, Zydus Pharms, Encube, G And W Labs Inc, Padagis Israel, Actavis Mid Atlantic, Amneal, Amring Pharms, Annora Pharma, Rising, Sandoz, Actavis Labs Fl, Sinotherapeutics Inc, and Teva Pharms Inc. and is included in twenty-nine NDAs.

The generic ingredient in MESALAMINE is mesalamine. There are twenty-eight drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Mesalamine

A generic version of MESALAMINE was approved as mesalamine by PADAGIS ISRAEL on September 17th, 2004.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for MESALAMINE?
  • What are the global sales for MESALAMINE?
  • What is Average Wholesale Price for MESALAMINE?
Drug patent expirations by year for MESALAMINE
Drug Prices for MESALAMINE

See drug prices for MESALAMINE

Drug Sales Revenue Trends for MESALAMINE

See drug sales revenues for MESALAMINE

Recent Clinical Trials for MESALAMINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Tanta UniversityN/A
AHS Cancer Control AlbertaPhase 2
Fedaa Abd El-monem Kamal El-deen Kotkata Faculty of Pharmacy, Tanta UniversityPhase 2

See all MESALAMINE clinical trials

Pharmacology for MESALAMINE
Drug ClassAminosalicylate
Medical Subject Heading (MeSH) Categories for MESALAMINE
Paragraph IV (Patent) Challenges for MESALAMINE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
DELZICOL Delayed-release Capsules mesalamine 400 mg 204412 1 2014-06-17
CANASA Suppository mesalamine 1000 mg 021252 1 2013-05-24
APRISO Extended-release Capsules mesalamine 0.375 g 022301 1 2012-04-03
ASACOL HD Delayed-release Tablets mesalamine 800 mg 021830 1 2011-07-13
LIALDA Delayed-release Tablets mesalamine 1.2 g 022000 1 2009-12-16
ASACOL Delayed-release Tablets mesalamine 400 mg 019651 1 2007-06-22

US Patents and Regulatory Information for MESALAMINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zydus Pharms MESALAMINE mesalamine TABLET, DELAYED RELEASE;ORAL 091640-001 Jun 5, 2017 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Zydus Pharms MESALAMINE mesalamine TABLET, DELAYED RELEASE;ORAL 203286-001 Jul 21, 2017 AB RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva Pharms Usa MESALAMINE mesalamine CAPSULE, DELAYED RELEASE;ORAL 207873-001 May 9, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mylan MESALAMINE mesalamine SUPPOSITORY;RECTAL 204354-001 Nov 24, 2015 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mylan MESALAMINE mesalamine TABLET, DELAYED RELEASE;ORAL 203574-001 Nov 20, 2018 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novast Labs MESALAMINE mesalamine CAPSULE, EXTENDED RELEASE;ORAL 218410-001 Aug 22, 2024 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.